Shexiang Tongxin Dropping Pill Protects Against Chronic Heart Failure in Mice via Inhibiting the ERK/MAPK and TGF-β Signaling Pathways

Shuying Zhang, Hanbing Liu, Qianqian Fang, Houhong He, Xiaoyan Lu, Yì Wáng, Xiaohui FanFrontiers in Pharmacology 2021 · DOI

TL;DR

This study investigates the molecular mechanisms behind Shexiang Tongxin Dropping Pill's (STDP) protective effects against chronic heart failure (CHF) in mice. By combining network pharmacology and transcriptome sequencing, the researchers identified that STDP improves cardiac function and reduces fibrosis and hypertrophy by inhibiting the ERK/MAPK and TGF-β signaling pathways.

What Problem Does This Paper Address?

Chronic heart failure (CHF) is a significant global health issue with high mortality and morbidity. While traditional Chinese medicine preparations like Shexiang Tongxin Dropping Pill (STDP) show promise in clinical settings for cardiovascular diseases, including CHF, their underlying molecular mechanisms remain largely unknown. Existing treatments often have side effects or are poorly tolerated by some patients, highlighting the need for new therapeutic strategies. This paper aims to bridge this knowledge gap by elucidating how STDP exerts its beneficial effects on CHF at a molecular level.

Methods

The researchers employed a multi-faceted approach:

  • CHF Model Creation: A mouse model of CHF was established using transverse aortic constriction (TAC) surgery, a standard method to induce pressure overload and heart failure.
  • Efficacy Evaluation: The therapeutic effects of STDP were assessed using echocardiography (to measure cardiac function like cardiac output, ejection fraction, and fractional shortening), Masson's trichrome staining (to detect myocardial fibrosis), and wheat germ agglutinin (WGA) staining (to measure cardiomyocyte size and hypertrophy).
  • Network Pharmacology: A CHF disease network was constructed by integrating existing cardiovascular disease-related genes with transcriptome sequencing data. This network was analyzed to identify key targets and pathways involved in CHF and STDP's action.
  • Whole-Transcriptome Sequencing: This technique was used to comprehensively analyze gene expression changes in the heart tissue of CHF mice treated with STDP compared to control groups. This allowed for the identification of differentially expressed genes (DEGs) and provided directional information (up/downregulation) that network pharmacology alone cannot provide.
  • Pathway Enrichment Analysis: Kyoto Encyclopedia of Genes and Genomes (KEGG) and Ingenuity Pathways Analysis (IPA) were used to identify significantly enriched pathways affected by STDP treatment.
  • In Vivo Validation: Key findings from the network and pathway analyses were validated experimentally using quantitative real-time polymerase chain reaction (qRT-PCR) to confirm gene expression levels and Western blot analysis to assess protein phosphorylation levels of key signaling molecules (ERK1/2 and Smad3).

Datasets

  • Cardiovascular Disease-Related Genes: A dataset of genes related to cardiovascular diseases was extracted from the [email protected] database.
  • Sequenced Genes: Whole-transcriptome sequencing data from mouse heart tissue was generated and uploaded to the Gene Expression Omnibus (GEO) database under accession number GSE185631.
  • Protein-Protein Interaction (PPI) Data: The STRING database was used to obtain protein-protein interaction information for network construction.

Key Insights and Ideas

  • Multi-Target, Multi-Pathway Action: STDP doesn't act on a single target but rather modulates a complex network of genes and pathways, aligning with the holistic nature of traditional Chinese medicine.
  • Recovery of Gene Expression Imbalance: STDP administration significantly reversed the imbalanced gene expression patterns observed in the TAC-induced CHF model, with a substantial number of genes showing a high efficiency of recovery.
  • Dual Inhibition of Key Pathways: The study strongly implicates the inhibition of both the ERK/MAPK and TGF-β signaling pathways as the primary mechanisms by which STDP exerts its protective effects. These pathways are known to be critical in the development of cardiac fibrosis and hypertrophy.
  • Validation of Molecular Mechanisms: The in vivo validation experiments, particularly the reduction in phosphorylated ERK1/2 and Smad3 levels, provide direct evidence for STDP's inhibitory action on these key signaling cascades.

Key Results

  • Improved Cardiac Function: STDP treatment significantly improved cardiac output (CO), left ventricular ejection fraction (LVEF), and left ventricular fractional shortening (LVFS) in CHF mice.
  • Reduced Cardiomyocyte Hypertrophy: STDP administration significantly attenuated the increase in cardiomyocyte cross-sectional area observed in the CHF model.
  • Ameliorated Cardiac Fibrosis: Masson's trichrome staining revealed that STDP treatment markedly reduced interstitial fibrosis in the left ventricular myocardium of CHF mice.
  • Gene Expression Recovery: STDP administration led to the recovery of 395 imbalanced genes in the CHF disease network, with 77.7% of these genes showing over 80% recovery efficiency.
  • Pathway Enrichment: Pathways related to fibrosis, energy metabolism, and inflammation were highly enriched after STDP treatment. Specifically, the ERK/MAPK and TGF-β pathways were predicted to be significantly affected.
  • Protein Level Confirmation: Western blot analysis confirmed that STDP treatment significantly reduced the phosphorylation levels of Smad3 and ERK1/2 in the heart tissues of CHF mice.

Limitations and Future Work

  • Limitations: While the study successfully identified key pathways and targets, the complex multi-component nature of STDP makes it challenging to pinpoint the exact active compounds responsible for each effect. The study primarily focused on the ERK/MAPK and TGF-β pathways, and other potentially involved pathways (e.g., energy metabolism, inflammation) could warrant further in-depth investigation.
  • Future Work: The authors suggest that STDP shows potential as a new therapeutic agent for CHF. Future research could focus on identifying the specific active components within STDP responsible for these effects and further exploring the roles of other enriched pathways like energy metabolism and inflammation. Investigating STDP's effects on novel targets like BRD4 and Wnt5a, which were also modulated by STDP, could also be a promising avenue.

Summary updated

Abstract

<b>Background:</b> Chronic heart failure (CHF) is a major public health problem with high mortality and morbidity worldwide. Shexiang Tongxin Dropping Pill (STDP) is a widely used traditional Chinese medicine preparation for coronary heart disease and growing evidence proves that STDP exerts beneficial effects on CHF in the clinic. However, the molecular mechanism of the therapeutic effects of STDP on CHF remains largely unknown. <b>Objective:</b> This study aimed to elucidate the mechanism of action of STDP against CHF by integrating network pharmacology analysis and whole-transcriptome sequencing. <b>Methods:</b> First, the mouse model of CHF was established by the transverse aortic constriction (TAC) surgery, and the efficacy of STDP against CHF was evaluated by assessing the alterations in cardiac function, myocardial fibrosis, and cardiomyocyte hypertrophy with echocardiography, Masson's trichrome staining, and wheat germ agglutinin staining. Next, a CHF disease network was constructed by integrating cardiovascular disease-related genes and the transcriptome sequencing data, which was used to explore the underlying mechanism of action of STDP. Then, the key targets involved in the effects of STDP on CHF were determined by network analysis algorithms, and pathway enrichment analysis was performed to these key genes. Finally, important targets in critical pathway were verified <i>in vivo</i>. <b>Results:</b> STDP administration obviously improved cardiac function, relieved cardiomyocyte hypertrophy, and ameliorated myocardial fibrosis in CHF mice. Moreover, STDP significantly reversed the imbalanced genes that belong to the disease network of CHF in mice with TAC, and the number of genes with the reverse effect was 395. Pathway analysis of the crucial genes with recovery efficiency revealed that pathways related to fibrosis and energy metabolism were highly enriched, while TGF-β pathway and ERK/MAPK pathway were predicted to be significantly affected. Consistently, validation experiments confirmed that inhibiting ERK/MAPK and TGF-β signaling pathways <i>via</i> reduction of the phosphorylation level of Smad3 and ERK1/2 is the important mechanism of STDP against CHF. <b>Conclusion:</b> Our data demonstrated that STDP can recover the imbalanced CHF network disturbed by the modeling of TAC through the multi-target and multi-pathway manner in mice, and the mechanisms are mainly related to inhibition of ERK/MAPK and TGF-β signaling pathways.
BibTeX
@inproceedings{zhang2021shexiang,
  author = {Shuying Zhang and Hanbing Liu and Qianqian Fang and Houhong He and Xiaoyan Lu and Yì Wáng and Xiaohui Fan},
  title = {{Shexiang Tongxin Dropping Pill Protects Against Chronic Heart Failure in Mice via Inhibiting the ERK/MAPK and TGF-β Signaling Pathways}},
  booktitle = {Frontiers in Pharmacology},
  year = {2021},
  doi = {10.3389/fphar.2021.796354},
}
Figure